Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
Public ClinicalTrials.gov record NCT03238703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR)
Study identification
- NCT ID
- NCT03238703
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Anastrozole Drug
- Exemestane Drug
- Laboratory Biomarker Analysis Other
- Letrozole Drug
- Quality-of-Life Assessment Other
- Questionnaire Administration Other
- Tamoxifen Citrate Drug
- Toremifene Citrate Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2018
- Primary completion
- Mar 13, 2023
- Completion
- Mar 13, 2025
- Last update posted
- Dec 26, 2018
2018 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03238703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 26, 2018 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03238703 live on ClinicalTrials.gov.